PL1622912T3 - 2-ALKINYLO i 2-ALKENYLO-PIRAZOLO-[4,3-E]-1,2,4-TRIAZOLO-[1,5-C]-PIRYMIDYNY JAKO ANTAGONIŚCI RECEPTORA ADENOZYNOWEGO A2A - Google Patents

2-ALKINYLO i 2-ALKENYLO-PIRAZOLO-[4,3-E]-1,2,4-TRIAZOLO-[1,5-C]-PIRYMIDYNY JAKO ANTAGONIŚCI RECEPTORA ADENOZYNOWEGO A2A

Info

Publication number
PL1622912T3
PL1622912T3 PL04760128T PL04760128T PL1622912T3 PL 1622912 T3 PL1622912 T3 PL 1622912T3 PL 04760128 T PL04760128 T PL 04760128T PL 04760128 T PL04760128 T PL 04760128T PL 1622912 T3 PL1622912 T3 PL 1622912T3
Authority
PL
Poland
Prior art keywords
triazolo
pyrazolo
alkynyl
alkenyl
receptor antagonists
Prior art date
Application number
PL04760128T
Other languages
English (en)
Inventor
Bernard R Neustadt
Jinsong Hao
Hong Liu
Craig D Boyle
Samuel Chackalamannil
Unmesh G Shah
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PL1622912T3 publication Critical patent/PL1622912T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL04760128T 2003-04-23 2004-04-21 2-ALKINYLO i 2-ALKENYLO-PIRAZOLO-[4,3-E]-1,2,4-TRIAZOLO-[1,5-C]-PIRYMIDYNY JAKO ANTAGONIŚCI RECEPTORA ADENOZYNOWEGO A2A PL1622912T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46484003P 2003-04-23 2003-04-23
EP04760128A EP1622912B1 (en) 2003-04-23 2004-04-21 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
PCT/US2004/012471 WO2004094431A2 (en) 2003-04-23 2004-04-21 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine a2a receptor antagonists

Publications (1)

Publication Number Publication Date
PL1622912T3 true PL1622912T3 (pl) 2009-11-30

Family

ID=33310963

Family Applications (2)

Application Number Title Priority Date Filing Date
PL378867A PL378867A1 (pl) 2003-04-23 2004-04-21 2-alkinylo- i 2-alkenylo-pirazolo- [4,3-e] -1,2,4-triazolo- [1,5-c]-pirymidynowi antagoniści receptora adenozynowego A <v>2a<D>
PL04760128T PL1622912T3 (pl) 2003-04-23 2004-04-21 2-ALKINYLO i 2-ALKENYLO-PIRAZOLO-[4,3-E]-1,2,4-TRIAZOLO-[1,5-C]-PIRYMIDYNY JAKO ANTAGONIŚCI RECEPTORA ADENOZYNOWEGO A2A

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL378867A PL378867A1 (pl) 2003-04-23 2004-04-21 2-alkinylo- i 2-alkenylo-pirazolo- [4,3-e] -1,2,4-triazolo- [1,5-c]-pirymidynowi antagoniści receptora adenozynowego A <v>2a<D>

Country Status (31)

Country Link
US (2) US6897217B2 (pl)
EP (1) EP1622912B1 (pl)
JP (2) JP4527712B2 (pl)
KR (1) KR100831107B1 (pl)
CN (1) CN100503609C (pl)
AR (1) AR044041A1 (pl)
AT (1) ATE432282T1 (pl)
AU (1) AU2004233334B2 (pl)
BR (1) BRPI0409787B8 (pl)
CA (1) CA2522813C (pl)
CL (1) CL2004000847A1 (pl)
CO (1) CO5700766A2 (pl)
CY (1) CY1109263T1 (pl)
DE (1) DE602004021250D1 (pl)
DK (1) DK1622912T3 (pl)
EC (1) ECSP056115A (pl)
ES (1) ES2326270T3 (pl)
HR (1) HRP20090394T1 (pl)
IL (1) IL171567A (pl)
MX (1) MXPA05011366A (pl)
MY (1) MY139344A (pl)
NO (1) NO332182B1 (pl)
NZ (1) NZ542823A (pl)
PE (1) PE20050141A1 (pl)
PL (2) PL378867A1 (pl)
PT (1) PT1622912E (pl)
RU (1) RU2373210C2 (pl)
SI (1) SI1622912T1 (pl)
TW (2) TWI375677B (pl)
WO (1) WO2004094431A2 (pl)
ZA (1) ZA200508489B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7313588B1 (en) * 2000-07-13 2007-12-25 Biap Systems, Inc. Locally executing software agent for retrieving remote content and method for creation and use of the agent
AU2002346503A1 (en) * 2001-11-30 2003-06-17 Schering Corporation Adenosine A2a receptor antagonists
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
MXPA05006790A (es) 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
ATE461932T1 (de) * 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
JPWO2006132275A1 (ja) 2005-06-07 2009-01-08 協和醗酵工業株式会社 運動障害の予防および／または治療剤
AR057817A1 (es) * 2005-09-19 2007-12-19 Schering Corp Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas
AR056080A1 (es) * 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
US8501997B2 (en) 2008-08-25 2013-08-06 Air Products And Chemicals, Inc. Curing agent for low temperature cure applications
US8512594B2 (en) * 2008-08-25 2013-08-20 Air Products And Chemicals, Inc. Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
KR20110128913A (ko) 2009-03-10 2011-11-30 다케다 야쿠힌 고교 가부시키가이샤 벤조푸란 유도체
EP2462144B1 (en) 2009-08-07 2017-09-20 Merck Sharp & Dohme Corp. PROCESS FOR PREPARING A 2-ALKYNYL SUBSTITUTED 5-AMINO-PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
RU2632659C2 (ru) * 2011-12-27 2017-10-09 Байо-Фарм Солюшнс Ко., Лтд. Фенилкарбаматные соединения для применения в предупреждении или лечении эпилепсии
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
WO2014139882A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
WO2021011670A1 (en) * 2019-07-17 2021-01-21 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists and uses thereof
CN115160120B (zh) * 2022-08-02 2024-08-27 乐威医药（江苏）股份有限公司 一种多烷氧基芳香酮的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US785906A (en) * 1904-12-06 1905-03-28 Albert P Mcbride Casing packer and shoe for gas or oil wells.
MX16165A (es) * 1988-05-25 1994-02-28 Dow Chemical Co Alcoxi-1,2,4-triazolo[1,5-c]pirimidin-2-sulfonamidas, procedimiento para su preparacion e intermediarios.
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
US5565460A (en) 1993-07-27 1996-10-15 Kyowa Hakko Koygo Co., Ltd. Therapeutic purine agents for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE19826843A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
PT1283839E (pt) * 2000-05-26 2005-08-31 Schering Corp Antagonistas do receptor a2a da adenosina
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
WO2002062801A1 (en) * 2001-02-05 2002-08-15 Otsuka Pharmaceutical Factory, Inc. Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンａ２ａ受容体アンタゴニストとしてのイミダゾ（４，３−ｅ）−１，２，４−トリアゾロ（１，５−ｃ）ピリミジン
MXPA05006790A (es) * 2002-12-19 2005-09-08 Schering Corp Usos de antagonistas del receptor adenosina a2a.
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
EP1622912B1 (en) 2009-05-27
KR20060005379A (ko) 2006-01-17
WO2004094431A2 (en) 2004-11-04
CA2522813C (en) 2009-09-08
PT1622912E (pt) 2009-08-17
TW201144317A (en) 2011-12-16
NO20055510D0 (no) 2005-11-22
DK1622912T3 (da) 2009-09-07
AU2004233334B2 (en) 2010-08-12
NZ542823A (en) 2009-03-31
CY1109263T1 (el) 2014-07-02
HK1085466A1 (en) 2006-08-25
AU2004233334A1 (en) 2004-11-04
US6897217B2 (en) 2005-05-24
ZA200508489B (en) 2007-04-25
NO332182B1 (no) 2012-07-23
IL171567A (en) 2013-01-31
TWI375677B (en) 2012-11-01
HRP20090394T1 (hr) 2009-08-31
CA2522813A1 (en) 2004-11-04
BRPI0409787B8 (pt) 2021-05-25
JP2006523619A (ja) 2006-10-19
MXPA05011366A (es) 2005-11-28
JP4527712B2 (ja) 2010-08-18
DE602004021250D1 (de) 2009-07-09
CN100503609C (zh) 2009-06-24
EP1622912A2 (en) 2006-02-08
WO2004094431A3 (en) 2004-12-02
MY139344A (en) 2009-09-30
BRPI0409787B1 (pt) 2018-08-21
CL2004000847A1 (es) 2005-03-11
US20040220194A1 (en) 2004-11-04
PE20050141A1 (es) 2005-04-01
ATE432282T1 (de) 2009-06-15
US20050222164A1 (en) 2005-10-06
TWI355381B (en) 2012-01-01
AR044041A1 (es) 2005-08-24
RU2005136166A (ru) 2006-06-10
RU2373210C2 (ru) 2009-11-20
NO20055510L (no) 2006-01-20
CN1777609A (zh) 2006-05-24
BRPI0409787A (pt) 2006-05-30
CO5700766A2 (es) 2006-11-30
SI1622912T1 (sl) 2009-10-31
JP2010059178A (ja) 2010-03-18
US7368449B2 (en) 2008-05-06
ECSP056115A (es) 2006-03-01
KR100831107B1 (ko) 2008-05-20
TW200427689A (en) 2004-12-16
PL378867A1 (pl) 2006-05-29
ES2326270T3 (es) 2009-10-06

Similar Documents

Publication Publication Date Title
IL178674A0 (en) PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
IL160878A0 (en) Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
PT1622912E (pt) Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina
IL220174A0 (en) 5-AMINO - {PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE}-2-AND 7-SUBSTITUTED DERIVATIVES AS ADENOSINE A2A RECEPTOR INHIBITORS
IL158214A0 (en) 8-heteroaryl xanthine adenosine a2b receptor antagonists
TWI365879B (en) A2b adenosine receptor antagonists
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161572A0 (en) Adenosine a2a receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
IL178365A0 (en) Selective antagonists of a2a adenosine receptors
HUP0402324A3 (en) [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
ZA200708524B (en) Process for preparing pyrido[2,3-D]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one derivatives
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
IL174771A0 (en) Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
ZA200908280B (en) Triazolo [1,5-A] quinolines as adenosine A3 receptor ligands
PL1678182T3 (pl) Sposób wytwarzania podstawionych 5-aminopirazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pirymidyn
PL370565A1 (pl) Pochodne 5-metoksy-8-arylo[1,2,4]triazolo[1,5-a]pirydyny
ZA200608778B (en) Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
HK1118045A (en) 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
HK1062534A (en) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists
TH0401001406A (th) 2-อัลไคนิล-และ 2-อัลคีนิล-ไพราโซโล-[4,3-e]-1,2,4-ไตรอะโซโล-[1,5-c]-ไพริมิดีน ที่เป็นแอนทาโกนิสท์ของตัวรับอะดีโนซีนA2a
HK1085202A (en) Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
HK1085201A (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists